Review of the annual Swiss Proteomics Meeting 2017

Presentation of Prof. Dr. Wollscheid was very successfull

The presentation of Prof. Dr. Wollscheid at the Bio-Technopark was a successful start of the new seminar series.


October 4th 2016, Schlieren:apero-bio-technopark-presentation-wollscheid-oktober-2016

Last week Dualsystems invited Prof. Wollscheid to give a presentation in a new seminar series at the Bio-Technopark in Schlieren. Nearly 80 people listened intensely to Prof. Bernd Wollscheid’s talk about “Decoding Ligand-Receptor Interactions”. Prof. Wollscheid presented his work that is trying to bridge the gap between the genotype and the phenotype and especially focusing on the protein-protein interactions at the surfaceome. After his impressive talk and during the party that followed Prof. Wollscheid had lively discussions with many participants and tried to answer all upcoming questions.

Prof. Dr. Bernd Wollscheid is a Principal Investigator and Head of the Biomedical Proteomics Platform at the Department of Health Sciences and Technology of Swiss Federal Institute of Technology in Zurich, Switzerland.


Dualsystems is looking for a Proteomics Specialist (Scientist 60%-100%)

Now, we are looking for a

Proteomics Specialist (Scientist 60%-100%)

to cover for a maternity leave.

Your responsibilities include

  • Proteomics data analyses (LTQ Orbitrap, Progenesis etc.)
  • Perform customer projects and internal method development projects in the wet lab for LRC-TriCEPs
  • Cell culture
  • FACS
  • Sample preparation for LC-MS/MS
  • Develop with the team the expansion of the current Services

Interested? More details and information on this site

Example with LRC-TriCEPS applied to human primary T-cells

The LRC-TriCEPS  applied to human primary T-cells

Zellwerk GmbH, Germany and Dualsystems Biotech AG, Zurich joined forces and conducted successfully an entire LRC- TriCEPSTM experiment on primary T-cells.

Positive control ligand (included in the kit): Anti-CD28 antibody the protein CD28
Ligand of interest: Anti-TCR2 α/β antibody
Cells used: human primary T-cells

Read all detail from the experiment about Example of LRC-TriCEPS T-cellsProtein level Volcano plot of LRC-TriCEPS

Next generation TriCEPS now available at Dualsystems Biotech

TriCEPSTM V.3.0 enables receptor identification for your orphan ligands at the surface of living cells without genetic manipulation.

Key features of the new TriCEPSTM V.3.0 and LRC- TriCEPSTM technology are: Read more

Dualsystems Biotech collaborates with Shantani Proteome Analytics

Dualsystems Biotech AG Press Release

Dualsystems Biotech AG collaborates with Shantani Proteome Analytics Pvt. Ltd. to partner business development activities for the two companies


Schlieren, Switzerland, Feb. 2016: – Dualsystems Biotech AG has announced today it will partner with Shantani Proteome Analytics Pvt. Ltd. to support each other in business development.


The partnership will combine the complementary strengths of Dualsystems, a leading service provider for target deconvolution of large molecules with the strengths of Shantani a leading service providing company for target deconvolution of small molecules.


Dualsystems provides the ligand-receptor capture (LRC-TriCEPS) technology developed by Prof. Bernd Wollscheid and licensed in from the ETHZ. The LC-MS/MS based technique is the only technology worldwide to identify the unknown receptors of a ligand on the living cells. The LRC-TriCEPS Technology uses a proprietary tri functional crosslinker molecule called TriCEPSTM to identify targets for large molecules (biotherapeutics/biologics) located in the cell membrane. The technology is able to identify the targets of peptides, proteins, antibodies and viruses while the target cell is still alive during ligand-target interaction. Next to the main targets, the technology will also identify off targets and therefore provides crucial information for selecting the right drug candidate.


Shantani is a privately-held biotechnology company that provides customized target identification solutions utilizing both traditional and novel chemical-proteomics based technologies. Shantani’s proprietary technology portfolio include Unique Polymer Technology (UPT) that utilizes specifically designed affinity matrix to immobilize the small molecule without any need of its derivatization and Sub Cellular Location Specific Target Capture Technology (SCLS) that utilizes sub-cellular location specific peptide probes to capture targets from specific cellular location. These technologies can achieve false positive target identification rates as low as 20%. Shantani’s technologies provides an unbiased approach to identify few yet ‘rightful’ targets of small molecule that eventually adds in lead optimization, lead selectivity/toxicity profiling and understanding action mechanism of the small molecule.


Contact for Dualsystems:
Dualsystems Biotech AG
Dr. Paul Helbling
Tel: +41 44 738 50 00
Contact for Shantani:
Shantani Proteome Analytics Pvt. Ltd.
Dr. Chaitanya Saxena
Tel: + +91 20 6410 3918

Dualsystems on Swiss National TV

The cover story about the startup company Topadur Pharma AG is now online on Swiss National Television SRF / Eco.
See Paul from #Dualsystems Biotech AG in this documentary (see at 15:38 min.)




We are lucky to have now a small biotech cluster in our building.

New publication in Nature Communications using the LRC-TriCEPS technology in collaboration with Alisson Gontijo

Target Identification publication at the EBR magazine April 2015

Target-identificationDo you need target identification of your ligand? Ligand-receptor capture (LRC-TriCEPSTM) a new approach to find the targets in the cell membrane on the living cells.

Read the article at the EBR magazine (site 25) for more details or the pdf.

EBR Magazin-April-15-Dualsystems-Ligand-receptor

Affinity and receptor expression limits tested for LRC-TriCEPS

Dualsystems Biotech AG is testing the limits of the LRC-TriCEPSTM (CaptiRec) technology using antibodies with different affinities against the same target and cells expressing the target receptor with different expression levels.



Details of the assesment see here